All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
Insulet
Insulet announces positive study data for Omnipod 5 for type 1, type 2 diabetes
Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]
How Insulet created its next-gen Omnipod 5
Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January. Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery […]
Diabetes tech is off to a hot start in 2022
Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
Insulet posts Street-beating Q4 with Omnipod revenues up nearly 20% from 2020
Insulet (NSDQ:PODD) this evening reported fourth-quarter results that came in ahead of the Wall Street consensus forecast amid strong sales growth. The Acton, Massachusetts–based maker of Omnipod insulin delivery systems posted profits of $29.2 million, or 42¢ per share, on sales of $307.7 million for the three months ended Dec. 31, 2021, for a massive […]
Insulet, Nintendo use ‘Animal Crossing’ video game to promote inclusivity for diabetes community
Insulet (NSDQ:PODD) announced today that new features set to debut on Nintendo’s Animal Crossing video game are inspired by people with diabetes. Acton, Massachusetts–based Insulet aims to promote representation and inclusion for the diabetes community through an activation on Animal Crossing: New Horizons. Starting today, Feb. 17, players can download design codes to access custom […]
Insulet appoints Elizabeth Weatherman to board of directors
Insulet (NSDQ:PODD) announced that Elizabeth (Bess) Weatherman was appointed to its board of directors. Weatherman — a veteran dealmaker in the health technology space — will stand for election by stockholders at the company’s 2022 annual meeting and has been named to the board’s Compensation Committee. Acton, Massachusetts–based Insulet said in a news release that […]
FDA clears Insulet’s next-generation Omnipod 5 wearable insulin delivery pump
Insulet (NSDQ:PODD) announced today that it received FDA clearance for its Omnipod 5 automated insulin delivery system. FDA clearance for the next-generation version of the company’s wearable insulin delivery pump system covers individuals aged six years and older with type 1 diabetes. The platform provides easier glucose management, with no multiple daily injections, no tubes […]
Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022
With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a significant regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As […]
Report: Insulet expects delays in FDA review for Omnipod 5 with launch pushed back
The highly anticipated launch of the Insulet (NSDQ:PODD) Omnipod 5 may not come as soon as thought as an FDA review drags on. SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of […]
